FORT LAUDERDALE, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., , a pioneer in human laser optical imaging systems, announced that it will feature the new RSNA Molecular Imaging Zone logo in its exhibit at RSNA 2006, to reflect the role of optical technologies in RSNA’s newly designated subspecialty.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
The Molecular Imaging Zone is designed to introduce general radiologists to molecular imaging, enabling them to learn the concepts at their own pace. Among the topics featured in the MI Zone’s debut are optical imaging and cell tracking using targeted imaging agents. As part of the Company’s technical exhibit, IDSI will present work-in-progress results of in-vivo human breast imaging using fluorescence compounds and will feature the latest CTLM and multimodality breast imaging studies from global sites.
Tim Hansen, Chief Executive Officer, Imaging Diagnostic Systems, said, “We are pleased to be a part of the Molecular Imaging Zone. IDSI’s many pioneering efforts in optical molecular imaging have centered on deriving functional information about molecular and cellular processes. As we have successfully applied these techniques to women’s health through our CT laser breast imaging technology, we have also developed the LILA capabilities for pre-clinical small animal imaging.”
LILA is a helical, optical CT scanner that simultaneously acquires optical attenuation and green fluorescent protein (GFP) image data. It images fluorescence from GFP, expressed by the DNA of jellyfish, which has been transfected into mammalian cells such as cancer tissue. LILA also images the distribution of specific fluorescent probes in animals and measures tissue optical absorption at near-infrared wavelengths to provide an anatomic reference for the fluorescence distribution. In September 2005, IDSI granted Bioscan, Inc. an exclusive worldwide license to manufacture and distribute optical imaging equipment incorporating IDSI’s Laser Imager for Lab Animals (LILA) technology.
RSNA 2006 is the 92nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, which will be held November 26-30 in Chicago, Illinois. The meeting, which attracts over 60,000 attendees, is reporting pre-registration figures of 17,986 total health professionals, including approximately 6,000 international attendees. IDSI will be exhibiting in Hall A, booth #4702, McCormick Place South Building.
Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is limited by United States Federal Law to investigational use only in the United States. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com
Photo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.
CONTACT: Rick Lutz, Investor Relations of Imaging Diagnostic Systems,Inc., +1-404-261-1196, or lcgroup@mindspring.com
Web site: http://www.imds.com/
